NapaJen Pharma has developed a proprietary drug delivery system (DDS) that enables the efficient and selective delivery of oligonucleotide-based therapies specifically targeting immune cells. This innovative platform addresses significant challenges in the field of nucleic acid therapeutics, such as instability, low bioavailability, and poor cellular uptake. By utilizing schizophyllan (SPG), a beta-glucan that binds to the Dectin-1 receptor found on antigen-presenting immune cells like dendritic cells and macrophages, NapaJen's technology facilitates the targeted delivery of oligonucleotides. This approach not only enhances the therapeutic potential of nucleic acid drugs but also significantly shortens the timeline from target identification to lead optimization in drug development.

The company's dual-pronged development strategy includes both internal drug development programs and collaborative efforts with other biotechnology and pharmaceutical companies. NapaJen's DDS technology is versatile, applicable to a wide range of nucleic acids, and is designed to create drug candidates for various immune-related conditions, including cancer, transplantation, and infectious diseases. The platform has demonstrated a promising safety profile, with no observed toxicity in non-human primate studies, and is currently undergoing first-in-human clinical trials. This unique capability positions NapaJen Pharma as a partner of choice for organizations seeking to advance their own oligonucleotide therapeutics.

United States

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.

NapaJen Pharma

Company Details